Insulin degludec injection (Tresiba) and insulin degludec/insulin aspart injection (Ryzodeg 70/30) were approved by the FDA on Sept. 25 to improve glucose control in adults with diabetes. The former, a long-acting insulin analog for both type 1 and 2 diabetes, is subcutaneously administered once daily at any time of day. The latter, administered once or twice daily, is a mixture of a long-acting insulin analog (insulin degludec) and a rapid-acting human insulin analog (insulin aspart). In clinical trials, the most common adverse reactions associated with both drugs were hypoglycemia, allergic reactions, injection-site reactions, lipodystrophy, itching, rash, edema, and weight gain. Both drugs are contraindicated for patients with diabetic ketoacidosis, according to an FDA press release.